BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Clinical Safety Data for ChromaDex, Inc.'s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris


6/13/2012 10:35:13 AM

IRVINE, Calif., June 13, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today its patented pTeroPure (pterostilbene) was shown to be safe for human consumption according to data from the first clinical trial of the substance. The findings, based on a study with pTeroPure, were presented at the 6th World Congress on Polyphenols Applications in Paris, France on June 7, 2012.(1) Pterostilbene is an antioxidant found in blueberries and other berries and believed by many experts to have a number of health benefits. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

"The safety of pterostilbene has previously been demonstrated in numerous cell and animal studies and we are pleased to find it translates to humans as well," said the study's principle investigator Daniel Riche, PharmD, Cardiometabolic Clinic Coordinator at the University of Mississippi School of Pharmacy. "These results further support pTeroPure's self-affirmed GRAS status and should leave no doubt that it is safe for human use in consumer products."

The study, a double-blind, randomized, placebo-controlled trial, included 80 adults who were given 100 to 250 mg per day of pTeroPure or placebo for 6-8 weeks. The results showed a lack of adverse reactions and no major adverse events. Data analyses from the trial on the effects of pTeroPure on blood pressure, triglycerides, cholesterol and oxidative stress are currently underway, and results are expected to be made public following acceptance in a peer-reviewed journal. The study was a collaboration between the University of Mississippi and ChromaDex.

Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals), resulting in more prolonged antioxidant activity. Along with a number of other effects, pterostilbene has shown great promise for supporting heart health, cognitive function and anti-aging.

"ChromaDex is committed to investing in human studies to provide the clinical evidence for our novel ingredients that the industry expects," said Frank Jaksch Jr., CEO and co-founder of ChromaDex. "These safety results fulfill an important prerequisite to expanding pTeroPure into our various business channels in the United States and abroad. We also are optimistic about the efficacy data, scheduled to be released within a few months. This is only one of our many planned studies intended to contribute to our mission of bringing solutions to our customers to help promote health and wellness."

pTeroPure is the key novel ingredient in BluScience, ChromaDex's recently launched line of dietary supplements. BluScience, which is now available at a major drug store chain, GNC and an online retailer, Drugstore.com, is expected to be available in more than 25,000 retail stores by year-end 2012, as well as through major online retailers.

About ChromaDex®:
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights. The company recently launched its BluScience line of dietary supplements, now available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S. through a distribution agreement with one of the largest pharmaceutical distributors in North America. BluScience is also available at a prominent online retailer, as well as a national health and nutrition products retailer. Capitalizing on the diverse potential applications of the product, ChromaDex is also investigating pTeroPure for the skincare and pharmaceutical markets, among others. For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

(1) McEwen CL. Analysis of safety from a human clinical trial with pterostilbene. Poster presentation at: International Society of Antioxidants in Nutrition and Health (ISANH) 6th World Congress on Polyphenols Applications: Paris Polyphenols 2012. June 7-8, 2012, Paris France.

ChromaDex Investor Contact:

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

or

Alex Partners, LLC
Scott Wilfong, President
425-242-0891
Scott@alexpartnersllc.com

ChromaDex Contact:

Laura Carney, Executive Assistant
949-419-0288
laurac@chromadex.com

SOURCE ChromaDex Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES